Hepatic ischemia/reperfusion injury (IRI) and associated inflammation contributes to liver dysfunction and complications after liver surgery and transplantation. Mesenchymal stem cells (MSCs) have been reported to reduce hepatic IRI because of their reparative immunomodulatory effects in injured tissues. Recent studies have highlighted beneficial effects of extracellular vesicles from mesenchymal stem cells (MSC-EV) on tissue injury. The effects of systemically administered mouse bone marrow-derived MSC-EV were evaluated in an experimental murine model of hepatic IRI induced by cross-clamping the hepatic artery and portal vein for 90 minutes followed by reperfusion for periods of up to 6 hours. Compared with controls, intravenous administration of MSC-EV 30 minutes prior to IRI dramatically reduced the extent of tissue necrosis, decreased caspase 3-positive and apoptotic cells, and reduced serum aminotransferase levels. MSC-EV increased hepatic messenger RNA (mRNA) expression of NACHT, LRR, and PYD domainscontaining protein 12, and the chemokine (C-X-C motif) ligand 1, and reduced mRNA expression of several inflammatory cytokines such as interleukin 6 during IRI. MSC-EV increased cell viability and suppressed both oxidative injury and nuclear factor kappa B activity in murine hepatocytes in vitro. In conclusion, the administration of extracellular vesicles derived from bone marrow-derived MSCs may ameliorate hepatic IRI by reducing hepatic injury through modulation of the inflammatory response.
Hepatic ischemia/reperfusion injury (IRI) is an important contributor to outcomes of liver surgery and transplantation. Complications associated with IRI after liver transplantation can range from early graft dysfunction to graft nonfunction. Cold ischemia occurring during organ preservation may be followed by warm ischemia after liver transplantation. Ischemic injury has been implicated in poor outcomes with the use of organ donations following cardiac death, where warm ischemic injury may be an important initiating event. IRI can also contribute to outcomes following hepatic resection and resuscitation after hemorrhagic shock. (1) (2) (3) (4) In all of these settings, hepatocellular injury and IRI can occur as a result of acute interruption of blood flow to the liver with subsequent reperfusion. The subsequent acute inflammatory cascade leads to significant damage to hepatocytes and nonparenchymal cells.
Mesenchymal stem cells (MSCs) are attractive for tissue replacement because of their regenerative ability, multipotent capability, and immunoregulatory Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AML12, alpha mouse liver 12; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CXCL1, chemokine (C-X-C motif) ligand 1; CXCR2, chemokine (C-X-C motif) receptor 2; DiR, 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindotricarbocyanine iodide; DMEM, Dulbecco's Modified Eagle Medium; EV, extracellular vesicles; FBS, fetal bovine serum; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H & E, hematoxylin-eosin; H 2 O 2 , hydrogen peroxide; IFN, interferon; IL, interleukin; IP, intraperitoneal; IRI, ischemia/reperfusion injury; IV, intravenous; IVIS, in vivo imaging system; mRNA, messenger RNA; MSC, mesenchymal stem cell; MSC-EV, extracellular vesicles from mesenchymal stem cells; NF-jB, nuclear factor kappa B; NLR, NOD-like receptor; NLRC4, NOD-like receptor C4; NLRP12, NACHT, LRR, and PYD domains-containing protein 12; PBS, phosphate-buffered saline; po, per os; PTGS2, prostaglandin-endoperoxide synthase 2; ROS, reactive oxygen species; T-Bil, total bilirubin; SC, subcutaneous; SEM, standard error of the mean; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. effects. Indeed, MSCs derived from bone marrow, umbilical cord, or adipose tissue can alleviate hepatic IRI by inhibiting apoptosis, (5) (6) (7) (8) suppressing oxidative stress (8, 9) or immunomodulation. (10) Although MSCs can differentiate and replace tissue, cells may not survive long enough to do so following their infusion. (11) More likely, the therapeutic benefit observed with MSCs is associated with release of paracrine factors. Systemic injection of conditioned medium from MSCs provides a significant survival benefit in vivo, and it prevents the release of liver injury biomarkers, reduces hepatocyte apoptosis, and increases proliferation. (12) (13) (14) (15) These paracrine effects could be mediated through secreted proteins or through cellderived extracellular vesicles (EVs). However, the contributions of the latter during hepatic IRI are not well established.
Protective effects of MSCs during ischemic injury have been reported in several animal models. (5) (6) (7) (8) (9) (14) (15) (16) (17) (18) (19) (20) Moreover, EVs have been associated with protective effects in cardiac or renal ischemia. (9, 16, 19, 20) EVs are a heterogeneous population that comprise microvesicles and exosomes. (21, 22) These vesicles are enclosed by a lipid bilayer membrane, and their contents include proteins, lipids, RNA, or DNA molecules. (23) We have recently shown that extracellular vesicles derived from mesenchymal stem cells (MSC-EV) can attenuate mortality in experimental hepatic failure in mice and, further, that MSCs derived from EV can protect hepatocytes from apoptosis and reduce injury. (24) In the present study, we evaluated the effects of MSC-EV on experimental hepatic IRI to ascertain their potential role in ameliorating tissue injury and inflammation.
Materials and Methods

CELLS AND CELL CULTURE
Alpha mouse liver 12 (AML12), mouse hepatocyte cells were obtained from American Type Culture Collection (Rockville, MD) and maintained in Dulbecco's Modified Eagle Medium (DMEM)/F-12 1 Glutamax containing 6.7 ng/mL of selenium, 10 lg/mL of insulin, 5.5 lg/mL of transferrin, 40 ng/mL of dexamethasone (Sigma-Aldrich, St Louis, MO), and 10% fetal bovine serum (FBS). Mouse (C57BL/6) bone marrow-derived MSC were obtained from Life Technologies (Grand Island, NY) and maintained in DMEM/F-12 1 Glutamax containing MSCqualified FBS. All media were obtained from Life Technologies (Grand Island, NY). Primary hepatocytes were isolated from 6-to 8-week-old C57BL/6 mice (Jackson Labs, ME) as described by Klaunig et al. with modifications. (25) Under isoflurane anesthesia, an abdominal incision was made, the hepatic portal vein was cannulated, and a 2-step buffer liver perfusion was performed. The liver was removed, and hepatocytes were separated by gentle mincing and filtering using a cell strainer. Hepatocytes were plated (250,000/well) into collagen coated 6-well dishes.
BIODISTRIBUTION OF SYSTEMICALLY ADMINISTERED MSC-EV
MSC-EV were incubated with 6 lmol/L DiR (1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindotricarbocyanine iodide; Life Technologies, Grand Island, NY) (7) for 30 minutes, then washed with phosphate-buffered saline (PBS) and collected after ultracentrifugation. The labeled MSC-EV (2.0 3 10 10 ) were administrated via subcutaneous (SC), intraperitoneal (IP), intravenous (IV), or per os (po) to healthy mice, with control mice receiving no treatment. Organs were harvested 6 hours later, and labeled EVs were quantitated ex situ using an in vivo imaging system (IVIS; PerkinElmer, Waltham, MA).
HEPATIC ISCHEMIA/ REPERFUSION
All animal studies were performed in accordance with committee-approved institutional animal care and use protocols (number A11514-14). First, MSC-EV (2 3 10 10 particles/body) or PBS (vehicle) in a 200-lL volume were administered via tail vein injection to 10-to 12-week-old male C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME). After 30 minutes, mice were anesthetized with IP ketamine (100 mg/kg) and xylazine (10 mg/kg), and a midline laparotomy incision was performed. The hepatic artery and the portal vein above the branching to the right lateral segment were clamped using an atraumatic clip with jaws 1 mm wide 3 5 mm long (catalogue number 14120, World Precision Instruments, Sarasota, FL), thus resulting in partial (70%) hepatic ischemia (Supporting Fig. 1 ). (26) The liver was kept moist at 378C with gauze soaked in sterile saline, and body temperature was maintained at 378C using a heating blanket. The clip was removed after 90 minutes. Sham surgeries were identical except that hepatic blood flow was not reduced with an atraumatic clip. After 1, 3, or 6 hours of reperfusion, blood was collected by cardiac puncture, and the liver was removed and snap-frozen in liquid nitrogen or fixed in 4% buffered formalin.
IN VITRO HYPOXIA/NORMOXIA STUDIES
Primary mouse hepatocytes were cultured in 6-well dishes at 250,000 cells/well and allowed to attach overnight. Cells were then treated with 1.8 3 10 8 mMSC-EV particles/mL or PBS (controls), and placed in a self-contained and sealed hypoxia chamber within an incubator with 5% CO 2 , 21% O 2 , balanced with N 2 , and 95% humidity. For hypoxic conditions, the inlet and outlet ports were opened and purged with 5% CO 2 and 95% N 2 at 20 psi for 4 minutes, after which the ports were sealed for 90 minutes. For normoxic conditions, cells were placed in the chamber with the clamps open for 90 minutes. After that time, the chambers were incubated with the ports open for a further 6 hours; cells were collected; and RNA was isolated.
MEASUREMENT OF REACTIVE OXYGEN SPECIES
AML12s were plated into 96-well plates (1 3 10 4 cells/well) and incubated overnight; 100 lL of 0.1X 2 0 ,7 0 -dichlorodihydrofluorescin diacetate/media was added and cells incubated at 378C for 60 minutes, cultivated in 100 lL of vesicle-depleted medium with 2 3 10 10 particle/mL MSC-EV or PBS (vehicle) for 24 hours. The media was removed and replaced with media with or without 50 mM hydrogen peroxide (H 2 O 2 ). Intracellular reactive oxygen species (ROS) concentrations were measured using OxiSelect Intracellular ROS Assay Kit (Cell Biolabs, San Diego, CA). Fluorescence was measured using a FLUOstar Omega reader (BMG Labtech, Cary, NC) at 480/530 nm.
NUCLEAR FACTOR KAPPA B ACTIVITY
Nuclear factor kappa B (NF-jB) promoter activity was determined using a Ready-To-Glow secreted luciferase reporter system (Clontech, Mountain View, CA). AML12 cells were plated in 6-well plates (2310 5 cells/ well) and transfected with the pNF-jB-MetLuc or pMetLuc2-Control plasmids using lipofectamine 2000 (Invitrogen, Carlsbad, CA). After transfection, 5310 4 cells AML12 were incubated in 24-well plates overnight and then cultured in 100 lL vesicle-depleted medium with 2 3 10 10 particles/mL MSC-EV or PBS (vehicle) for 24 hours. Cells were then incubated with or without 50 mM H 2 O 2 for 1 hour; 50 lL of culture media from each well was transferred into a 96-well white plate, 5 lL of 1X substrate/reaction buffer added, and the luminescence was measured using a FLUOstar Omega reader (BMG Labtech, Cary, NC).
EV ISOLATION, HISTOPATHOLOGY, WESTERN BLOT, POLYMERASE CHAIN REACTION, CELL PROLIFERATION, AND PROTEIN ASSAYS
Details are outlined in the Supporting Information.
STATISTICAL ANALYSIS
Data were expressed as mean and standard error from at least 3 replicates. Comparisons between groups were performed using the 2-tailed Student t test, and results were considered to be statistically significant when P < 0.05.
Results
EV CAN BE ISOLATED FROM MOUSE BONE MARROW-DERIVED MSC IN VITRO
An ultracentrifugation-based protocol was used to isolate EV released by mouse bone marrow-derived MSC in vitro. Isolated vesicles had a mean size of 115 6 48 nm and peak size 89 nm by nanoparticle tracking analysis and expressed exosome-associated proteins by immunoblot analysis (Supporting Fig. 2 ). The size and surface markers support the presence of significant enrichment of exosomes within the isolated EV pool. However, the presence of other types of vesicles cannot be excluded, and we have therefore referred to the isolated vesicles as EV.
BIODISTRIBUTION OF SYSTEMICALLY ADMINISTERED MSC-EV
In order to identify an optimal and effective method for systemic administration, we examined the uptake and biodistribution of MSC-EV administered via different routes in 2 mice each. Organ uptake was assessed 6 hours after administration of labeled EVs by different routes. Intraorgan accumulation of labeled MSC-EV was greatest with either IV or IP administration. In both cases, accumulation of MSC-EV was most prominent in the liver and spleen compared with other organs (Fig. 1) . Thus, IV administration is an effective and efficient route for the delivery of EVs to the liver.
MSC-EV PROTECT AGAINST EXPERIMENTAL HEPATIC IRI
The effects of MSC-EV were then evaluated in a murine model of hepatic IRI. MSC-EV (2 3 10 10 particles) or PBS (vehicle) was injected via the tail vein 30 minutes prior to ischemia (Fig. 2) . In the PBS control group, a temporal increase in serum alanine aminotransferase (ALT) levels was noted at 1, 3, and 6 hours of reperfusion. In contrast, serum ALT levels in the MSC-EV group reached a peak at 3 hours of reperfusion, but a decrease was noted at 6 hours of reperfusion. Furthermore, reductions in aspartate aminotransferase (AST), alkaline phosphatase (ALP), and serum blood urea nitrogen and a trend toward a reduced creatinine were also noted in mice that received MSC-EV compared with PBS controls after a 6-hour reperfusion. Hematoxylineosin (H & E) staining of liver tissues obtained from the PBS (vehicle control) group 6 hours after reperfusion showed widespread necrosis around the central veins, whereas the extent of necrosis was significantly reduced in livers from the group that received MSC-EV (Fig. 3) . Immunohistochemistry for activated caspase 3 revealed positive cell expression in many cells, and particularly around zone 1 in the PBS group. On the other hand, a significantly reduced number of caspase 3-positive cells were observed in the MSC-EV group. Thus, MSC-EV can reduce biochemical and histological manifestations of hepatic injury following experimental hepatic IRI.
Within the liver, macrophages and Kupffer cells contribute to the regulation of hepatic inflammation and hepatocyte death. We observed a reduction in the number of F4/80-positive cells (macrophage/Kupffer cells) in the PBS group, with the number of cells decreasing over time. A similar reduction was also noted following sham surgery but not in the MSC-EV group (Fig. 3) . Indeed, in the MSC-EV-treated group, the number of F4/80-positive cells increased at 1 hour of reperfusion and FIG. 1 . Biodistribution of MSC-EV. EVs labeled by DiR were administrated via SC, IP, IV, or po routes to healthy mice (n 5 2 each). (A) Accumulation of labeled EVs in these organs were detected ex vivo after 6 hours, and (B) the intensity of fluorescent signal was measured using an IVIS, and the average shown here. Hepatic uptake was noted with IP or IV, with the latter having the greatest uptake.
FIG. 2.
MSC-EV reduce biochemical markers of hepatic injury during hepatic IRI in vivo. (A) Experimental schema. MSC-EV or vehicle controls (PBS) were administered IV 30 minutes prior to induction of hepatic ischemia for 90 minutes, followed by reperfusion for up to 6 hours. (B) Serum biochemical studies 6 hours after reperfusion in mice receiving PBS or MSC-EV or in sham-operated controls. Data are expressed as the mean 6 standard error of the mean (SEM; n 5 6 mice/group). *P< 0.05, **P < 0.01, ***P < 0.001. (C) Time course of serum ALT levels in mice during hepatic IRI. Data are expressed as the mean 6 SEM (n 5 3-6 mice/group). *P < 0.05 or **P < 0.01 in EV-treated versus PBS controls at the indicated time points after reperfusion. 
MSC-EV MODULATE RELEASE OF INFLAMMATORY MEDIATORS FROM HEPATOCYTES IN VITRO
To understand the potential role of immune and inflammation-associated mediators, we examined the effect of MSC-EV on the secretion of cytokines and chemokines from murine hepatocytes in vitro. Assays were performed on culture supernatant obtained from AML12 cells incubated with or without MSC-EV after 24 hours. MSC-EV decreased secretion of inflammatory cytokines, such as tumor necrosis factor (TNF) a, interleukin (IL) 1a, IL1b, IL6, IL12, or interferon (IFN) c compared with control. In contrast, a significant increase in chemokine (C-X-C motif) ligand 1 (CXCL1) and monocyte chemoattractant protein 1 occurred with MSC-EV (Fig. 4) . Next, we examined effects of MSC-EV on gene expression, and observed a >1.5-fold increase in messenger RNA (mRNA) expression of 18 inflammasome, chemokine, or cytokine genes in vivo following administration of MSC-EV compared with PBS (vehicle control; Supporting Table 1 ). These included several inflammasome-related genes, such as NACHT, LRR, and PYD domains-containing protein 12 (NLRP12); Pycard; NAIP1; NLRP1A; or NLRC5; and the chemokine CXCL1 mRNA (Fig. 5) . In contrast, a decreased mRNA expression of other chemokines such as CCL7 and CXCL3 as well as several cytokines such as IFNb1, IFNc, IL1b, IL33 were observed with MSC-EV. The most prominent among these was a >1.5-fold decrease in IL6 mRNA. We further examined mRNA expression in primary mouse hepatocytes after 6 hours of normoxia with or without prior exposure to 90 minutes of hypoxia (Supporting Table 2 ). The potential contribution of nonparenchymal cells to 
MSC-EV ATTENUATE OXIDATIVE STRESS AND NF-jB ACTIVITY IN HEPATOCYTES
In order to ascertain the potential effect of MSC-EV on hepatocyte injury, we examined cell viability in AML12 murine hepatocytes incubated with MSC-EV (0-1310 10 particles/mL) for 24 hours (Supporting Fig. 3) . The results indicate that MSC-EV can directly reduce hepatocyte injury in vitro. The observations made from the in vivo studies indicated that MSC-EV could, in addition, modulate inflammatory responses during hepatic IRI. Oxidative injury associated with an increase in ROS and NF-jB activity can contribute to hepatocyte injury during hepatic IRI. (27) Thus, we then evaluated the ability of MSC-EV to dampen or ameliorate the effect of MSC-EV on oxidative stress and NF-jB activation in hepatocytes in vitro. For these studies, we evaluated the effects of MSC-EV on H 2 O 2 -induced ROS generation and NF-jB activity in AML12 cells. An increase in ROS activity was observed following exposure to H 2 O 2 for an hour. This was significantly reduced in the presence of preincubation with MSC-EV for 24 hours (Fig. 6) . Similarly, the increase in activity of NF-jB was also reduced by MSC-EV. Thus, MSC-EV could modulate responses to oxidative stress during hepatic IRI and dampen the inflammatory responses that contribute to injury.
MSC-EV ENHANCE NLRP12 AND CXCL1 MRNA EXPRESSION IN THE LIVER
The direct effects of MSC-EV on hepatocyte gene expression were evaluated in vitro. RNA was extracted from AML12 murine hepatocytes incubated with either 1310 10 particles/mL MSC-EV or PBS (vehicles) for 6 hours, and quantitative real-timepolymerase chain reaction was performed. The most significant increase in expression of inflammasome genes was noted for NLRP12, which was increased >3-fold (P < 0.001) in the MSC-EV group compared with either PBS or the sham groups. NLRP12 mRNA expression was significantly increased in vivo during hepatic IRI following administration of the MSC-EV group compared with the sham or PBS groups. Even though an increase in NLRP12 was only appreciated after 6 hours of reperfusion, there was no significant change in NLRP12 mRNA expression in the PBS control group (Fig. 7 ).
An increase in mRNA expression of several genes such as NLRP3, CXCL1, CXCL3, mitogen-activated protein kinase 13 or PTGS2 was noted in hepatocytes incubated with MSC-EV compared with vehicle controls (Supporting Table 3 ). Among these, a >1.5-fold increase in CXCL1 mRNA was noted in liver tissue of IRI mice receiving EV in vivo and in hepatocytes 10 particles/mL MSC-EV in the presence or absence of H 2 O 2 . Data are expressed as the mean 6 SEM (n 5 3/group) *P < 0.05, **P < 0.01, ***P < 0.001. treated with MSC-EV in vitro compared with controls ( Supporting Fig. 4) . Consistent with this, a significant increase in CXCL1 mRNA was also observed within liver tissue in the MSC-EV group compared with the PBS group after 3 hours and 6 hours of reperfusion (Fig. 8) . Although an increase in CXCL1 mRNA was also noted after sham surgery and in livers from mice receiving PBS, this was further significantly increased with MSC-EV after IRI at 6 hours of reperfusion. An increase in cell viability was observed in vitro, in AML12 cells incubated with recombinant CXCL1 (0-100 ng/mL) for 24 hours (Supporting Fig. 5 ). CXCL1 mRNA is among several mRNA identified as being selectively enriched within EV derived from MSC, compared with their expression in the cells of origin (Supporting Table 4 ). We therefore postulate that CXCL1 mRNA is enriched within MSC-EV, and the transfer of CXCL1 to hepatocytes following uptake of MSC-EV could contribute to a reduction of hepatic IRI.
Discussion
The multipotent capacity of MSCs is an attractive property that supports their use as therapeutic agents to enhance tissue repair and regeneration. (28, 29) In addition to an ability to de-differentiate, MSCs are capable of modulating inflammatory and immune responses. (6, 30, 31) Amelioration of experimental hepatic IRI by bone marrow-or adipose-derived MSCs has been observed in several studies in rodents. (5) (6) (7) (8) (32) (33) (34) These effects have been presumed to reflect the regenerative properties of MSCs, but they occur rapidly and inconsistent with the time required for tissue replacement. Moreover, MSCs are short-lived when IV administration is used. (35, 36) Thus, we and others have postulated that the observed beneficial effects are mediated by soluble or acellular factors such as EV released by MSCs. We have identified that MSC-EV can localize to the injured liver after systemic administration. MSC-EV have advantages over the use of MSC for therapeutic use by avoiding undesirable effects associated with use of cellular material. The size differences between MSCs (15-19 lm) (37) and MSC-EV The time course of NLRP12 mRNA level in liver tissue of IRI mice. *P < 0.05, ***P < 0.001 between groups at the indicated times after reperfusion. (B) NLRP12 mRNA level in hepatic IRI mice at 6 hours after reperfusion. ***P < 0.001. Data are expressed as the mean 6 SEM (n 5 3-6 mice/ group). (C) NLRP12 mRNA was assessed in primary mouse hepatocytes cultured in the presence of MSC-EV or PBS (controls) after 6 hours of normoxia with or without prior exposure to 90-minute hypoxia. Data represent fold-change of NLRP12 mRNA with MSC-EV compared with PBS (controls). N7.5 5 normoxia 7.5 hours, H1.5/N6 5 1.5 hours hypoxia followed by 6 hours normoxia.
(115 6 48 nm) also provide further advantages. Thus, although IV administration of MSCs may become trapped in the lungs (37, 38) and form potentially lethal microemboli, (39) we did not observe any similar effects following IV administration of MSC-EV in our studies.
MSC-EV reduced the expression of inflammatory mediators both in vivo and in vitro. The rapid initiation of a sterile inflammatory response could contribute to hepatic IRI. Such responses could be mediated through the release of endogenous danger signals that activate the innate immune system. The NOD-like receptors (NLRs) are a major class of cytosolic pattern recognition receptors (PRR). Activation of some family members such as NLRP1, NLRP3, and NLRC4 in response to recognition of intracellular danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) can result in inflammasome formation. Subsequently, caspase 1 activation results in posttranslational cleavage of pro-IL1b and pro-IL18 into their active forms. IL1b and IL18 are important mediators of the inflammatory and cell death response. (40, 41) Caspase 1 and inflammasome-dependent pathways may contribute to hepatic IRI. However, even though MSC-EV increased expression of several NLRs, hepatic IL1b expression was decreased during IRI by MSC-EV. Rather than through direct effects on proinflammatory NLR expression, our observations imply that the effects of MSC-EV involve attenuation of inflammation through NLRP12. NLRP12 is a negative regulator of inflammatory activity in vitro in the immune system and other settings, through attenuation of noncanonical NF-jB signaling. (42, 43) MSC-EV suppressed both experimentally induced oxidative stress and NF-jB activity in hepatocytes, and expression of several inflammation-associated cytokines such as IL6 and IL1b that are transcriptionally regulated by NF-jB activation. (43) These effects could serve to protect the liver during inflammatory stress. Consequently, attenuation of inflammatory responses associated with tissue injury could represent a mechanism for the beneficial effects of MSC-EV during hepatic IRI. Thus, targeting NLRP12-mediated anti-inflammatory responses to modulate hepatic IRI warrants further evaluation as a therapeutic strategy.
In addition to ameliorating the sterile inflammatory response, MSC-EV can directly modulate inflammatory responses such as through CXCL1, a secreted chemokine which binds the G-protein coupled receptor chemokine (C-X-C motif) receptor 2 (CXCR2) to recruit and activate leukocytes. In mice, CXCL1 deficiency is associated with colitis and defects in immune cell recruitment to the lung. An increased expression of CXCR2 on hepatocytes has been reported during The time course of CXCL1 mRNA level in liver of hepatic IRI mice. *P < 0.05; ***P < 0.001 between EV-treated and control groups at the indicated time points. (B) CXCL1 mRNA level in hepatic IRI mice at 6 hours after reperfusion. (C) CXCL1 mRNA was assessed in primary mouse hepatocytes cultured with MSC-EV or PBS (controls) for 6 hours under normoxia with or without prior exposure to 90-minute hypoxia. Data represent foldchange of NLRP12 mRNA with MSC-EV compared with PBS (controls). ***P < 0.001. Data are expressed as the mean 6 SEM (n 5 3-6 mice/group). N7.5 5 normoxia 7.5 hours, H1.5/N6 5 1.5 hours hypoxia followed by 6 hours normoxia.
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hepatic injury in several studies, and receptor engagement altering hepatocyte survival and proliferation in a dose-dependent mechanism. (44) CXCL1 is upregulated in liver allografts that experience early allograft dysfunction, the clinical sequelae of IRI, following transplantation. (45) MSC-EV increased CXCL1 release from AML12 hepatocytes in vitro. CXCL1 mRNA expression was increased during hepatic IRI in vivo, with expression further enhanced by MSC-EV. Furthermore, CXCL1 directly increased hepatocyte proliferation, consistent with other reports. (46) Thus, we speculate that CXCL1 may participate in tissue restoration responses to injury. Although not conclusively demonstrated, increased hepatic expression of CXCL1 could contribute to recruitment of cells that release NLRP12. The number of F4/80-positive cells in the liver were significantly increased in the MSC-EV or sham group compared with PBS (vehicle) after reperfusion, and negatively correlated with serum ALT levels. A contribution of F4/80-expressing cells with attenuation of injury is consistent with other reports of hepatic protection linked to Kupffer cell-dependent expression of anti-inflammatory cytokines such as IL10. (47) The precise involvement of Kupffer cells needs to be examined because their functional inactivation has been reported to attenuate injury during reperfusion. (48, 49) In conclusion, these studies support the use of EVs derived from MSCs as a therapeutic strategy to alleviate hepatic IRI following hepatic surgery or liver transplantation. The regenerative capacity of donor organs is reduced by hepatic IRI that accompanies liver transplantation. Reducing this injury could increase the use of marginal livers that are obtained from extended criteria donors such as older donors or following cardiac death for transplantation. Therapeutic interventions that alleviate hepatic IRI will increase the donor organ pool available for transplantation and thereby reduce mortality from advanced liver disease.
